** Noxopharm NOX.AX soars 12.9% to A$0.096, snapping three sessions of declines
** Stock set for biggest intraday pct gain since Nov. 15, 2024
** Biotech co says its lupus medication has passed a set of pre-clinical safety tests, a requisite for drug development prior to Phase 1 clinical trial
** Around 326,347 shares traded, 2.3x the 30-day avg
** NOX gains 3.2% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。